Serous Cystadenocarcinoma of the Ovary

Serous cystadenocarcinoma is the most common form of ovarian cancer, accounting for about three out of four cases. This cancer begins in the cells that line the ovaries, fallopian tubes, or the abdomen’s inner lining, and often grows and spreads quickly.

Table of contents

• What Is Serous Cystadenocarcinoma Ovary
• Associated Anatomy
• Understanding High-Grade Disease
• Causes and Risk Factors
• Symptoms
• Diagnosis
• Treatment
• Prognosis and Living with the Disease

What Is Serous Cystadenocarcinoma Ovary

Serous cystadenocarcinoma is a type of cancer that develops in the female reproductive system. It is the most common form of ovarian cancer, which is a disease where cells in the ovaries grow out of control^[1]. This cancer type accounts for approximately 75 percent of all epithelial ovarian cancers, which are cancers that begin in the cells on the surface of the ovaries^[1][11].

The term “serous” means that the tumor develops from the serous membrane, which is the layer of cells lining certain organs in the body^[1]. Until recently, doctors believed that ovarian cancers started on the surface of the ovaries themselves. However, researchers now understand that many cases of serous ovarian cancer actually begin in the epithelium (the cells lining the surface) of the fallopian tubes before spreading to the ovaries^[1][5].

Because serous cystadenocarcinoma can originate from the ovaries, fallopian tubes, or the peritoneum (the inside lining of the abdomen), doctors often group these cancers together. They share similar characteristics, develop from the same type of tissue, and are treated in similar ways^[5][12].

• Ovaries
• Fallopian tubes
• Peritoneum (abdominal lining)
• Uterus

Associated Anatomy

The ovaries are part of a woman’s reproductive system. Each ovary is about the size of an almond and produces eggs as well as hormones like estrogen and progesterone^[4]. The female reproductive system contains two ovaries, one on each side of the uterus.

The fallopian tubes are thin tubes that connect the ovaries to the uterus. The fringed ends of these tubes, called fimbriae, sit close to the ovaries in the space inside the abdomen^[12]. The peritoneum is a thin layer of tissue that lines the inside of the abdomen and covers the organs within it.

Understanding High-Grade Disease

Most cases of serous cystadenocarcinoma are classified as high-grade serous carcinoma. In medical terms, a tumor’s “grade” refers to how abnormal the cancer cells look under a microscope compared to healthy cells^[1][5].

When doctors examine high-grade serous carcinoma cells under a microscope, they see cells that appear highly abnormal. These cells are also poorly differentiated, meaning they do not have a clear structure or pattern like normal cells do. This disorganized appearance indicates that the tumor cells grow quickly and tend to spread rapidly to other parts of the body^[1].

The term “high-grade” specifically refers to cancers classified as Grade 3, which is the most aggressive grade. About three out of four people with ovarian cancer have this high-grade type^[5].

Causes and Risk Factors

Cancer develops when genes undergo changes that disrupt how cells normally function. These gene changes can cause cells to grow too quickly and ignore signals that would normally slow their growth^[5].

In serous cystadenocarcinoma, cells often have specific types of gene changes. More than 96 percent of cases studied show mutations (changes) in a gene called TP53. This gene normally produces a protein that prevents cancer development^[2][5]. In fact, 19 out of 20 people with this cancer have changes in the TP53 gene^[5].

About one in four people with serous cystadenocarcinoma have changes in genes called BRCA1 or BRCA2. These gene mutations cause additional damage to build up within cells and are usually passed down within families. People born with changes in these genes have a higher risk for ovarian cancer, breast cancer, or both^[2][5].

Several factors can increase a person’s risk of developing serous ovarian cancer:

• Older age—the disease most commonly affects women aged 65 and older^[2]
• Obesity
• Hormone replacement therapy after menopause
• Pelvic inflammatory disease
• Previous breast cancer—people who have had breast cancer are three times more likely to develop this type of ovarian cancer^[5]

On the other hand, certain factors can reduce the risk, including giving birth, breastfeeding, and using oral contraceptives (birth control pills)^[5].

Symptoms

When serous cystadenocarcinoma first develops, it often does not cause noticeable symptoms. When symptoms do appear, they are usually mistaken for other, more common conditions^[4][5]. This is one reason why most cases are not diagnosed until the cancer has grown or spread.

Common signs and symptoms may include:

• Abdominal bloating or swelling
• Abdominal or pelvic pain or discomfort
• Feeling full quickly when eating
• Frequent need to urinate
• Weight loss
• Fatigue
• Back pain
• Changes in bowel habits, such as constipation^[4]

If these symptoms persist for more than two weeks, it is important to see a doctor. Early detection can improve outcomes^[17].

Diagnosis

Because effective screening tests for ovarian cancer are lacking, most women are diagnosed at an advanced stage of the disease^[2]. Several tests and procedures are used to diagnose serous cystadenocarcinoma:

During a pelvic exam, a doctor inserts gloved fingers into the vagina while pressing on the abdomen to feel the pelvic organs, including the ovaries and uterus. This allows the doctor to check for any abnormalities in size or shape^[10].

Imaging tests create pictures of the inside of the body. Tests such as ultrasound or CT scans (computed tomography scans) of the abdomen and pelvis can help determine the size, shape, and structure of the ovaries^[10].

Blood tests may be performed to check overall health and look for tumor markers. One important test measures a protein called CA-125 (cancer antigen 125), which is often found on the surface of ovarian cancer cells. However, these tests alone cannot confirm whether someone has cancer—they provide clues that help with diagnosis^[10][7].

Sometimes a doctor cannot be certain of a diagnosis until surgery is performed to remove an ovary and test it for signs of cancer. During this surgery, a biopsy (removal of a small tissue sample) is taken and examined under a microscope^[10].

Genetic testing may be recommended to look for gene changes that increase the risk of ovarian cancer, such as BRCA1 or BRCA2 mutations. This information helps doctors make decisions about treatment and may be important for family members to know about their own risk^[10].

Treatment

The optimal treatment for serous cystadenocarcinoma typically involves a combination of surgery and chemotherapy^[4][7]. The goal is to remove as much of the cancer as possible and then use medication to destroy any remaining cancer cells.

Surgery aims to achieve complete cytoreduction, meaning the removal of all visible tumor tissue^[7]. This may involve removing one or both ovaries, the fallopian tubes, the uterus, and nearby tissue where cancer has spread. How much tissue needs to be removed depends on the stage of cancer at diagnosis and the patient’s overall health^[11].

Chemotherapy for serous ovarian cancer typically uses a combination of two drugs: carboplatin and paclitaxel^[7]. These medications work by killing cancer cells or stopping them from growing. Chemotherapy may be given before surgery to shrink tumors, after surgery to destroy remaining cancer cells, or both.

In addition to traditional chemotherapy, newer treatments are being used:

• Anti-angiogenic agents like bevacizumab can be added to chemotherapy. These drugs work by blocking the formation of new blood vessels that tumors need to grow^[7].
• PARP inhibitors are targeted drugs that can be used as maintenance therapy, especially for patients with BRCA mutations. These medications help prevent cancer from returning after initial treatment^[7].

For patients whose cancer returns (recurs), treatment options depend on how much time has passed since the initial treatment ended. This time period, called time to recurrence, helps determine which treatments will be most effective^[7].

Prognosis and Living with the Disease

Serous cystadenocarcinoma responds well to treatment if it is diagnosed during an early stage. However, most cases are diagnosed at a later stage, which presents greater challenges^[11].

Despite aggressive treatment that includes surgery, chemotherapy, anti-angiogenic agents, and PARP inhibitors, most patients with advanced disease will experience a recurrence, especially those with stage III-IV cancer^[7]. Studies have shown that certain gene expression patterns are associated with survival outcomes. Patients with BRCA1 or BRCA2 mutations have better odds of survival than patients without these mutations^[2].

Living with serous cystadenocarcinoma involves managing physical symptoms, treatment side effects, and emotional well-being. A balanced diet is important, especially during chemotherapy. Small, frequent meals of bland foods can help manage nausea. After treatment, a diet high in fruits and vegetables along with lean proteins supports overall health^[14][18].

Exercise can help offset side effects such as anxiety, fatigue, and sleep problems. Physical activity is an important part of maintaining quality of life during and after treatment^[14].

Regular follow-up care is essential after treatment. The CA-125 blood test is a reliable way to detect recurrences early^[7][16]. Patients should stay connected with their healthcare team and report any new or persistent symptoms promptly.